KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity (2018 - 2022)

TherapeuticsMD's Debt to Equity history spans 8 years, with the latest figure at -$0.04 for Q3 2022.

  • For Q3 2022, Debt to Equity rose 98.89% year-over-year to -$0.04; the TTM value through Sep 2022 reached -$0.04, up 98.89%, while the annual FY2021 figure was -$2.01, 4.91% down from the prior year.
  • Debt to Equity reached -$0.04 in Q3 2022 per TXMD's latest filing, up from -$3.48 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $23.98 in Q2 2019 to a low of -$19.41 in Q1 2021.
  • Average Debt to Equity over 5 years is -$0.33, with a median of -$1.96 recorded in 2021.
  • The largest YoY upside for Debt to Equity was 2711.34% in 2019 against a maximum downside of 1777.3% in 2019.
  • A 5-year view of Debt to Equity shows it stood at $0.75 in 2018, then skyrocketed by 2711.34% to $21.15 in 2019, then plummeted by 109.06% to -$1.92 in 2020, then fell by 4.91% to -$2.01 in 2021, then soared by 98.2% to -$0.04 in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Debt to Equity are -$0.04 (Q3 2022), -$3.48 (Q2 2022), and -$1.44 (Q1 2022).